A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Status:
RECRUITING
Trial end date:
2026-08-25
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of BGM0504 in patients with type 2 diabetes (T2D) with poor glycemic control only through diet and exercise.
The main purpose is to evaluate the clinical efficacy of BGM0504 injection monotherapy for 32 weeks compared with placebo in Chinese patients with type 2 diabetes with poor glycemic control only through diet and exercise, and to evaluate the clinical efficacy and safety of BGM0504 injection for 52 weeks of administration.
Phase:
PHASE3
Details
Lead Sponsor:
BrightGene Bio-Medical Technology Co., Ltd.
Collaborator:
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.